Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease. The commonly used treatments for PD include drug therapy and neurosurgery. At present, there is no definite method to prevent the development of the disease and new treatment schemes need to be explored. Ultrasound has been widely concerned and used as one of the treatment methods for PD due to its non-invasive, high spatial resolution and high penetrability characteristics. In recent years, MRI-guided focused ultrasound(MRgFUS) ablation technology, MRgFUS open blood brain barrier drug delivery technology, low-intensity focused ultrasound stimulation technology and sonogenetics have all achieved promising results in clinical research or preclinical animal models. MRgFUS ablation surgery is generally used to ablate unilateral nuclei to treat PD motor symptoms. This surgery has the advantages of non-invasiveness, small damage and quick effect, which shows a good application prospect in the treatment of PD. The blood brain barrier is a major obstacle for the effective delivery of macromolecule drugs to the brain. MRgFUS coupled with microbubbles can temporarily open the blood brain barrier, allowing drugs to enter the target area. The MRgFUS open blood brain barrier drug delivery technology has shown good therapeutic effect in PD animal models, its safety and reversibility have been preliminarily proved in human experiments. However, several key problems, such as effective ultrasound parameters, optimal microbubble size and administration dose, need to be resolved before clinical application. Low-intensity focused ultrasound stimulation technology is an emerging treatment method in recent years. It has demonstrated neuromodulation and neuroprotection functions in PD animal model studies, which can reverse animal movement disorders. low-intensity focused ultrasound stimulation is a potential treatment option for PD, but it also faces the problem of unstandardized treatment parameters. Sonogenetics is a new technology developed based on focused ultrasound, which is controllable in terms of spatiotemporal resolution and cell type. Several ultrasound-sensitive ion channels have been discovered, but whether these ion channels can be expressed in the human body and the related safety issues remain to be verified. This technology is currently in the early research stage and has great potential for development. The main progress of transcranial ultrasound in the treatment of PD in recent five years from the above four aspects are reviewed and some scientific problems are discussed in this paper, hoping to provide certain reference and help for the study of the pathogenesis and treatment of PD.